$1,410,000 of TAKEDA PHARMACEUTICALS AMERICA INC lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"FY 2025 Budget Resolution - Pharmaceutical Related Provisions Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Medicare telehealth proposals CMS Transparency in Coverage Final Rule (CMS-9915-F) Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills Bayh-Dole march-in rights policy issues Administration's Global Tax Proposal General issues around 2026 Reconciliation/Inbound Concerns General intellectual property policy issues Issues related to proposed Tariffs - all pharmaceutical related provisions Discussions around Supply Chain implications"
You can find more data on corporate lobbying on Quiver Quantitative.
TAK Hedge Fund Activity
We have seen 163 institutional investors add shares of TAK stock to their portfolio, and 158 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 4,012,456 shares (+1426.4%) to their portfolio in Q4 2025, for an estimated $62,554,189
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,854,069 shares (+100.9%) to their portfolio in Q4 2025, for an estimated $44,494,935
- TORONTO DOMINION BANK removed 2,181,100 shares (-72.6%) from their portfolio in Q4 2025, for an estimated $34,003,349
- UBS GROUP AG removed 1,770,446 shares (-30.0%) from their portfolio in Q4 2025, for an estimated $27,601,253
- MILLENNIUM MANAGEMENT LLC removed 1,666,117 shares (-65.2%) from their portfolio in Q4 2025, for an estimated $25,974,764
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,578,338 shares (-88.9%) from their portfolio in Q4 2025, for an estimated $24,606,289
- MORGAN STANLEY removed 1,317,213 shares (-17.1%) from their portfolio in Q4 2025, for an estimated $20,535,350
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
